Introduction
============

Numerous studies have shown that elevated blood pressure (BP) is a major risk factor for cardiovascular morbidity and mortality. This relationship, which has been demonstrated in a range of patient populations and age groups, is strong and continuous ([@b24-vhrm-4-1315]; [@b30-vhrm-4-1315]; [@b56-vhrm-4-1315]; [@b1-vhrm-4-1315]; [@b53-vhrm-4-1315]; [@b39-vhrm-4-1315]; [@b26-vhrm-4-1315]).

Blood pressure is a continuous variable with a normal distribution in the population ([@b39-vhrm-4-1315]; [@b7-vhrm-4-1315]). Thus, by necessity, any definition of 'hypertension' is arbitrary. However, there is a consensus among many of the major guidelines for the treatment of hypertension that individuals with a BP ≥ 140/90 mmHg should be regarded as hypertensive, and that attempts should be made to keep BP below this threshold in all individuals ([@b7-vhrm-4-1315]; [@b64-vhrm-4-1315]; [@b35-vhrm-4-1315]; [@b31-vhrm-4-1315]). Systolic and diastolic BP targets are generally lower in patients at high cardiovascular risk and in those with diabetes or renal disease ([@b7-vhrm-4-1315]; [@b64-vhrm-4-1315]; [@b31-vhrm-4-1315]).

Diastolic BP (DBP) has historically taken precedence over systolic BP (SBP) in the treatment of hypertension. This situation has arisen because early epidemiological and interventional trials focused primarily on the risks associated with DBP ([@b6-vhrm-4-1315]), a focus that has influenced subsequent clinical practice. However, a number of large, well-validated studies have shown that SBP is a better predictor of cardiovascular risk than DBP in most of the subjects allocated to chronic antihypertensive therapy in clinical practice. In addition to these observations, the increase in life expectancy observed over the last few decades in many developed countries means that the paradigm has shifted towards SBP ([@b6-vhrm-4-1315]).

Elevations in SBP frequently occur without elevations in DBP, a condition known as 'isolated systolic hypertension' (ISH: SBP ≥ 140 mmHg, DBP \< 90 mmHg) ([@b7-vhrm-4-1315]). Arterial stiffness, endothelial dysfunction, atherosclerosis, and oxidative stress all contribute to the development of ISH, which is the predominant type of hypertension in elderly patients ([@b59-vhrm-4-1315]; [@b63-vhrm-4-1315]). Since DBP is, by definition, normal in patients with ISH, aggressive lowering of DBP may not be an appropriate strategy for this patient group. Moreover, until recently, the development of new antihypertensive agents has focused almost exclusively on mechanisms that lead to decreased DBP, and drugs developed as a result of this strategy may not provide optimal management of elevated SBP. Drugs that have proven to be particularly useful in the treatment of ISH are nitrates, calcium channel blockers (CCBs) and agents that target the renin-angiotensin system (RAS, ie, angiotensin II receptor blockers \[ARBs\] and angiotensin converting enzyme inhibitors \[ACEIs\]) because these agents improve the large artery stiffness and early wave reflection that are major characteristics of this condition ([@b13-vhrm-4-1315]).

Importance of systolic blood pressure
=====================================

The importance of SBP as a predictor of cardiovascular risk has been demonstrated in a number of studies. This can be clearly seen in the classic meta-analysis of data from 61 prospective observational studies that involved almost 1,000,000 individuals with no vascular disease at baseline carried out ([@b26-vhrm-4-1315]). This analysis calculated the effect of a 20 mmHg difference in usual SBP on the risk of stroke and ischemic heart disease (IHD). The authors found that for individuals between the ages of 40 and 89 years, a usual SBP value that was lower by 20 mmHg was associated with significantly lower risk of death from stroke (hazard ratios, 0.36--0.67) and IHD (0.49--0.67) ([@b26-vhrm-4-1315]).

The importance of SBP as a predictor of outcome has also been demonstrated by the Blood Pressure Lowering Treatment Trialists' Collaboration in a study involving data from over 160,000 patients enrolled in placebo- and active-controlled randomized trials of antihypertensive treatment ([@b60-vhrm-4-1315]). This overview showed that the risks of stroke, major cardiovascular events, coronary heart disease (CHD), cardiovascular mortality, and total mortality were related to differences between treatments in SBP ([@b60-vhrm-4-1315]). Similar results were obtained by [@b54-vhrm-4-1315], [@b55-vhrm-4-1315] in two meta-analyses that examined the relationship between odds ratios for cardiovascular outcomes and differences in SBP among different antihypertensive agents ([@b54-vhrm-4-1315], [@b55-vhrm-4-1315]). The results of both meta-analyses led to the conclusion that differences in cardiovascular outcome can largely be attributed to differences in SBP ([Figure 1](#f1-vhrm-4-1315){ref-type="fig"}).

The three studies discussed above ([@b60-vhrm-4-1315]; [@b54-vhrm-4-1315], [@b55-vhrm-4-1315]) involved analysis of data from hypertensive patients with varying degrees of cardiovascular risk. However, the importance of SBP as a cardiovascular risk factor has also been demonstrated in subgroups of patients at particularly high risk, including those with type 2 diabetes. For example, in the United Kingdom Prospective Diabetes Study, each 10 mmHg reduction in usual SBP was associated with a significant 11% reduction in the risk of myocardial infarction ([@b1-vhrm-4-1315]).

These data demonstrate the strong association between SBP and cardiovascular risk. However, epidemiological data and demographic shifts also serve to emphasize the importance of SBP in the current management of hypertension. For example, data from the 2003--2004 National Health and Nutrition Examination Survey (NHANES) show that ISH is the most common type of hypertension among individuals at high cardiovascular risk (those with pre-existing CVD or with comorbidities that predispose to CVD) ([@b65-vhrm-4-1315]). Moreover, SBP is known to increase gradually with age whereas DBP tends to decrease in elderly individuals ([@b6-vhrm-4-1315]). Isolated systolic hypertension is thus likely to become increasingly prevalent since aging of the population is a feature of both developed and developing countries ([@b23-vhrm-4-1315]). Isolated systolic hypertension is associated with a high risk of cardiovascular events such as stroke ([@b49-vhrm-4-1315]; [@b52-vhrm-4-1315]; [@b28-vhrm-4-1315]; [@b19-vhrm-4-1315]), and the incidence of such complications can be significantly reduced by effective antihypertensive treatment ([@b49-vhrm-4-1315]; [@b52-vhrm-4-1315], [@b53-vhrm-4-1315]; [@b28-vhrm-4-1315]; [@b62-vhrm-4-1315]). Approximately 281,000 unnecessary cardiovascular events could be prevented, with a healthcare system cost saving of €1.26 billion (based upon 2002 costing), if the BP of all patients with hypertension in five European countries (France, Germany, Italy, Sweden, and the United Kingdom) was reduced to \< 140/90 mmHg ([@b17-vhrm-4-1315]). The predominance of ISH in elderly hypertensive patients is likely to explain the observation that the importance of SBP as a predictor of CHD risk increases with age ([@b24-vhrm-4-1315]).

Superior prediction of cardiovascular risk with systolic blood pressure
=======================================================================

Nearly 40 years ago, data from the Framingham Heart Study showed that SBP was more closely associated with risk of CHD than DBP ([@b24-vhrm-4-1315]). Although DBP was shown to be a more useful predictor of risk in hypertensive patients under 45 years old, for the majority of hypertensive patients, the ability of SBP to predict CHD was not improved by addition of DBP data ([@b24-vhrm-4-1315]). The superior predictive ability of SBP was more recently confirmed by the Prospective Studies Collaboration, a meta-analysis of 61 prospective observational studies that recorded BP and cause-specific mortality ([@b26-vhrm-4-1315]). In this study, [@b26-vhrm-4-1315] found that SBP at baseline was more informative than DBP as a predictor of stroke and IHD mortality. Moreover, the study concluded that, in middle-aged individuals, prolonged reductions in usual SBP of only 2 mmHg would lead to substantial reductions in the incidence of death secondary to stroke (7% reduction) and IHD or other vascular causes (10%) ([@b26-vhrm-4-1315]).

These findings are supported by those of [@b56-vhrm-4-1315] who found that SBP had a stronger association with cardiovascular risk than DBP in middle-aged and elderly individuals. At every level of DBP in this population, a higher SBP value was associated with greater cardiovascular risk and lower life expectancy ([@b56-vhrm-4-1315]). The results of one study, however, demonstrated that gender may be an important factor in determining the extent to which DBP also plays a role in cardiovascular risk in middle-aged patients (Benetos et al 2001). In this study, although SBP was strongly associated with mortality both in men and women, DBP was also an important predictive factor, but only in women (Benetos et al 2001).

More recently, [@b3-vhrm-4-1315] aimed to determine whether the high cardiovascular mortality rate of treated hypertensive patients was due to hypertension or to the presence of associated risk factors and/or diseases. Using cardiovascular mortality data from treated hypertensive patients (n = 8893) and from untreated age- and gender-matched normotensive and hypertensive controls (n = 25,880) enrolled in the Investigations Préventives et Cliniques cohort, [@b3-vhrm-4-1315] found that the two-fold increase in cardiovascular and coronary mortality that was apparent in treated hypertensive patients persisted after adjustment for cardiovascular risk factors. Adjustment for SBP was necessary to render the mortality rates similar in the two populations. Subsequent inclusion of DBP in the model did not modify the between-group risk ratio. These results indicate that the increased cardiovascular mortality in treated hypertensive patients is mainly due to uncontrolled SBP levels ([@b3-vhrm-4-1315]) ([Figure 2](#f2-vhrm-4-1315){ref-type="fig"}).

Systolic BP is also superior to DBP as a predictor of adverse renal outcomes in patients with diabetic nephropathy. [@b44-vhrm-4-1315] used data from 1590 hypertensive, diabetic patients enrolled in the Irbesartan Diabetic Nephropathy Trial to determine the effects of treatment allocation (irbesartan, amlodipine, or placebo), and baseline and mean follow-up SBP and DBP on progressive renal failure and all-cause mortality. [@b44-vhrm-4-1315] found that follow-up achieved SBP was the strongest predictor of an adverse renal outcome (doubling of serum creatinine or progression to end-stage renal disease). Moreover, the risk associated with inadequate control of SBP was substantial. Compared with patients who achieved SBP values \< 134 mmHg, those with SBP levels \> 149 mmHg had more than twice the risk of a renal endpoint. Also, values of baseline and achieved SBP that were lower by 20 mmHg were associated with relative risks of 0.79 and 0.52, respectively ([Table 1](#t1-vhrm-4-1315){ref-type="table"}). In contrast, there was no relationship between baseline or achieved DBP and progression of renal disease ([Table 1](#t1-vhrm-4-1315){ref-type="table"}) ([@b44-vhrm-4-1315]). Lowering of SBP was also associated with reduced risk of death. However, although the beneficial effects of lowering SBP were graded and continuous down to a level of 120 mmHg, the association with adverse renal outcomes showed evidence of a plateau below this level. Moreover, all-cause mortality showed a sharp increase at achieved SBP levels ≤120 mmHg ([@b44-vhrm-4-1315]). [@b44-vhrm-4-1315] concluded that a SBP target between 120 mmHg and 130 mmHg seems ideal in this population.

It is evident from the data described above that SBP is a more useful predictor of cardiovascular and renal events than DBP, although DBP should also be taken into consideration in younger patients and in women. Achievement of SBP targets should thus be given priority in the majority of patients receiving antihypertensive therapy.

Achievement of systolic blood pressure targets
==============================================

In spite of the growing recognition that adequate control of SBP is fundamental to reducing cardiovascular risk, a substantial proportion of patients still fail to achieve the target levels defined by current guidelines. For example, data from NHANES III show that SBP was controlled to \< 140 mmHg in only 34% of hypertensive patients (treated or untreated) ([@b12-vhrm-4-1315]). In contrast, 73% of patients achieved DBP control (\< 90 mmHg). More recent NHANES data (2003--2004) have shown that hypertensive patients who are receiving treatment but who are not at goal tend to be ≥ 20 mmHg above their SBP target, and \< 10 mmHg above their DBP target ([@b65-vhrm-4-1315]). This situation is not restricted to the United States. The Evaluation and Interventions for Systolic Blood Pressure Elevation -- Regional and Global (EISBERG) project, which analyzed data from more than 17,000 patients in seven countries (Canada, France, Germany, Italy, Spain, United Kingdom, and the United States), found that a substantially higher percentage of patients had DBP controlled to levels endorsed by national guidelines than SBP ([@b58-vhrm-4-1315]).

Such differences may result, in part at least, from the attitude of physicians, who tended to set less rigorous targets for SBP than DBP. A similar bias was reported in the Hypertension and Diabetes Screening and Awareness (HYDRA) study, which analyzed data from 45,125 primary care patients in Germany ([@b57-vhrm-4-1315]). In this study, elevated SBP levels were tolerated by doctors in 51% of affected patients. In contrast, elevated DBP levels were tolerated in only 41% of affected patients.

One might expect the situation to be better in intervention trials, where patient motivation and compliance are likely to be high, and the protocol is likely to emphasize achievement of target BP. However, even under these conditions, control of DBP is achieved more frequently than SBP control. For example, in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 67% of patients achieved SBP \< 140 mmHg, whereas 92% achieved DBP \< 90 mmHg ([@b9-vhrm-4-1315]). Overall control (\< 140/90 mmHg) was recorded in 66% of patients. Similar results were reported from the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) study, in which 69%--71% and 90% of patients maintained control of SBP and DBP, respectively ([@b5-vhrm-4-1315]). As in ALLHAT, overall control -- which occurred in 67%--69% of patients -- was similar to the proportion of patients who achieved control of SBP.

These results from individual studies are confirmed by those of [@b32-vhrm-4-1315] who used data from 10 controlled trials to show that far fewer patients achieve the level of SBP control recommended by guidelines than achieve the recommended DBP level ([Figure 3](#f3-vhrm-4-1315){ref-type="fig"}). Overall, DBP \< 90 mmHg and SBP \< 140 mmHg were achieved by approximately 90% and 50% of treated patients, respectively ([@b32-vhrm-4-1315]). Control of SBP and DBP was even worse among patients with diabetes. However, although the mean achieved DBP level was lower than the target in a number of studies involving diabetic patients, in no study did the mean achieved SBP level reach its target.

The relatively poor control of SBP identified in clinical trials is also apparent in specialist clinics and primary care practice. For example, in a specialist hypertension clinic that documented the effects of managing patients using a 'goal oriented' approach, 63% and 86% of patients achieved SBP \< 140 mmHg and DBP \< 90 mmHg, respectively ([@b51-vhrm-4-1315]). Achieving the level of BP control that is recommended for patients with diabetes proved particularly difficult. Only 23% of this group achieved the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC) VI SBP goal ([@b22-vhrm-4-1315]) for this population of \< 130 mmHg whereas 68% achieved their DBP goal (\< 85 mmHg) ([@b51-vhrm-4-1315]). Similar findings have been reported from primary care. For example, in the HYDRA study, 95% of patients with uncontrolled hypertension had elevated SBP levels ([@b57-vhrm-4-1315]). In contrast, DBP was elevated in only 50% of patients.

The consistent difference in the levels of SBP and DBP control achieved in interventional trials, specialist hypertension clinics, and primary practice suggests that controlling SBP is substantially more difficult than controlling DBP. Achieving overall control of BP in patients with ISH is thus particularly challenging. Moreover, SBP must be controlled in this population without excessive lowering of DBP (≤ 60 mmHg), because this degree of DBP reduction has been associated with reduced survival ([@b46-vhrm-4-1315]). This point is probably of particular importance in specific populations, such as diabetic patients, subjects with overt coronary artery disease and elderly hypertensives in whom attempted lowering of SBP to target levels of less than 130 mmHg is often associated with inordinate lowering of DBP that could lead to an excess in coronary ischemic events ([@b33-vhrm-4-1315]; [@b42-vhrm-4-1315] [@b37-vhrm-4-1315]).

Systolic blood pressure in hypertension guidelines
==================================================

Current guideline recommendations represent a paradigm shift towards SBP. This change of emphasis has been influenced by the increase in human life expectancy ([@b23-vhrm-4-1315]), by the results of numerous analyses showing that SBP is a better predictor of cardiovascular risk than DBP ([@b24-vhrm-4-1315]; [@b56-vhrm-4-1315]; [@b26-vhrm-4-1315]; [@b3-vhrm-4-1315]; [@b6-vhrm-4-1315]), and by recognition that poor control of SBP is largely responsible for the prevailing low rates of BP control ([@b29-vhrm-4-1315]; [@b18-vhrm-4-1315]). These factors have led to emphasis of the importance of SBP as a cardiovascular risk factor in the current treatment guidelines of the JNC VII and the World Health Organization/International Society of Hypertension (WHO-ISH) ([@b7-vhrm-4-1315]; [@b64-vhrm-4-1315]). Indeed, for patients at low-to-medium risk, the WHO/ISH guidelines recommend a target for SBP only (\<140 mmHg). This approach is justified by evidence from the STRAtegies of Treatment in Hypertension: Evaluation (STRATHE) study which showed that if SBP goals are achieved, DBP goals are also likely to be realized. For example, in the STRATHE study, only 3.4% of treated patients with stage 2 hypertension who achieved a SBP \< 140 mmHg retained a DBP ≥ 90 mmHg ([@b61-vhrm-4-1315]). In contrast, 16.6% of patients who achieved a DBP \< 90 mmHg retained a SBP ≥ 140 mmHg ([Figure 4](#f4-vhrm-4-1315){ref-type="fig"}).

New approaches in hypertension management
=========================================

Despite the fact that the literature shows that SBP is an extremely important target for blood pressure lowering, many physicians remain driven by target achievement for DBP. Hypertension thus remains poorly controlled. However, there have been changes in understanding of the necessary treatment algorithm and it is now well recognized that most patients will require combination therapy, initiated as first line or at least early, to achieve guideline BP targets ([@b31-vhrm-4-1315]). However, there is an inverse relationship between regimen complexity and patient adherence ([@b38-vhrm-4-1315]; [@b14-vhrm-4-1315]), and treatment regimens that involve administration of multiple drugs have consistently been associated with reduced compliance and adherence ([@b41-vhrm-4-1315]; [@b14-vhrm-4-1315]). The use of fixed-dose combinations represents an alternative approach to multiple drug therapy that has been shown to improve patient adherence ([@b10-vhrm-4-1315]; [@b2-vhrm-4-1315]). They also offer the possibility to combine agents with different pharmacological profiles to achieve additive effects with enhanced tolerability. The approach of using fixed-dose combinations as first-line treatment or earlier in patients with comorbidities that require rapid blood pressure reduction is endorsed by current guidelines ([@b7-vhrm-4-1315]; [@b31-vhrm-4-1315]).

A number of fixed-dose combination therapies are already in clinical use. These include ACEI/CCB ([@b21-vhrm-4-1315]; [@b47-vhrm-4-1315]), ACEI/diuretic ([@b34-vhrm-4-1315]; [@b40-vhrm-4-1315]), and ARB/diuretic ([@b25-vhrm-4-1315]; [@b48-vhrm-4-1315]; [@b36-vhrm-4-1315]). There are also fixed-dose combinations involving β-blockers, although the finding that β-blockers may be less effective for stroke prevention than other antihypertensive agents ([@b27-vhrm-4-1315]) has led to a trend towards guidelines placing less prominence on β-blocker-based therapy ([@b35-vhrm-4-1315]; [@b31-vhrm-4-1315]).

While there is a paucity of comparative data on the various combinations, the recent results from the Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial ([@b20-vhrm-4-1315]) gives an insight into the effectiveness of combinations involving CCB relative to those involving a diuretic. The results demonstrated that fixed-dose ACEI/CCB combination therapy significantly reduced the risk of morbidity and mortality relative to ACEI/diuretic therapy, despite similar BP reductions. It is unclear to what extent these findings are relevant to other fixed-dose combinations containing diuretic or CCBs; however, it would seem to support the use of fixed-dose combination therapy involving an agent acting on the RAS, and a CCB in hypertensive patients at high risk of developing coronary ischemic events.

A new strategy that will add to currently available treatment options is a fixed-dose combination of an ARB with the widely used CCB amlodipine. This promising new approach to treatment is currently represented by olmesartan medoxomil/amlodipine besylate and valsartan/amlodipine fixed-dose combinations. Aliskiren, an oral renin inhibitor, represents another approach to the management of hypertension that has recently become available. Aliskiren is available as monotherapy; a fixed-dose combination with hydrochlorothiazide (HCTZ) is also available in the United States.

Given the importance of controlling SBP, it is important to consider the impact of any new therapy on this aspect of hypertension. Certainly, the studies published to date on the efficacy of ARB/amlodipine combination therapy suggest that this strategy is capable of producing substantial reductions in SBP. For example, in a randomized, double-blind, placebo-controlled, factorial study involving 1940 patients with a mean baseline seated BP level of 164/102 mmHg, the combination of olmesartan medoxomil (40 mg/day) and amlodipine besylate (10 mg/day) was associated with mean SBP reductions of 30.1 mmHg after 8 weeks of treatment ([@b8-vhrm-4-1315]) ([Table 2](#t2-vhrm-4-1315){ref-type="table"}, [Figure 5](#f5-vhrm-4-1315){ref-type="fig"}).

Reductions in SBP approaching this magnitude have been reported in a registration study for valsartan/amlodipine combination therapy. The patients in this trial had less severe hypertension at baseline (mean seated BP, 156.7/99.1 mmHg) ([@b43-vhrm-4-1315]) than those in the olmesartan/amlodipine trial ([@b8-vhrm-4-1315]) and the mean SBP reduction observed after 8 weeks of amlodipine (10 mg/day)/valsartan (160 mg/day) was 27.8 mmHg ([Table 2](#t2-vhrm-4-1315){ref-type="table"}) ([@b43-vhrm-4-1315]). This dose is equivalent to the maximal marketed dose of the drug when administered as a fixed-dose combination in Europe.

The percentage of patients who achieved their target BP was reported in each of these ARB/amlodipine studies. However, the goal criteria in the olmesartan/amlodipine medoxomil study reflect current guideline recommendations (BP \< 130/80 mmHg for patients with diabetes, \<140/90 mmHg for all others \[[@b8-vhrm-4-1315]\]) and were more stringent than those defined in the valsartan/amlodipine study (DBP \< 90 mmHg or ≥ 10 mmHg decrease from baseline \[target SBP reduction not defined\] \[[@b43-vhrm-4-1315]\]). This difference invalidates comparison of goal rate achievement between the two studies.

Patients with severe hypertension require more substantial reductions in SBP. However, as demonstrated by [@b32-vhrm-4-1315] in a summary of data from 10 major clinical trials, higher initial BPs are typically associated with larger reductions during antihypertensive treatment ([Figure 3](#f3-vhrm-4-1315){ref-type="fig"}). This concept is borne out by the results of a relatively small, recent trial involving patients with a mean baseline BP of approximately 171/112 mmHg ([@b45-vhrm-4-1315]). Patients were treated for 6 weeks with amlodipine (5--10 mg/day)/valsartan (160 mg/day) or lisinopril (10--20 mg/day)/HCTZ (12.5 mg/day). The mean SBP reduction with the amlodipine regimen (n = 64) was --35.8 mmHg and with the lisinopril regimen (n = 66) it was --31.8 mmHg. The proportion of patients achieving SBP goal rates were not reported, but the DBP goal of \< 90 mmHg was achieved by 79.7 and 77.3% in the amlodipine and lisinopril groups, respectively.

The results of these recent clinical trials involving ARB/CCB combination therapy suggest that this therapeutic strategy offers potent lowering of BP and, in particular, substantial decreases in SBP. Given the strong association between SBP and cardiovascular risk, the advent of ARB/CCB combinations in convenient fixed-dose formulations provides a useful tool in the management of hypertension, and the consequent reduction of cardiovascular morbidity and mortality.

The SBP and DBP reductions achieved with aliskiren, the first-in-class renin inhibitor, are rather more moderate than those achieved with the ARB/CCB combinations. A recent review of clinical trials involving this agent showed that, in studies of patients with DBP ≥ 95 and \< 110 mmHg, aliskiren 150--300 mg as monotherapy or in combination with other antihypertensive agents produced reductions in SBP of between 8.7 and 21.2 mmHg, with approximately one third of these values falling between 14 mmHg and 16 mmHg ([@b11-vhrm-4-1315]). [Table 2](#t2-vhrm-4-1315){ref-type="table"} shows data from the aliskiren monotherapy and combination therapy trials that demonstrated the largest reductions in SBP.

One approach that may allow targeted control of SBP in the future is the use of advanced glycation endproduct (AGE)-crosslink breakers. Advanced glycation endproducts are believed to contribute to arterial stiffening and endothelial dysfunction, both of which increase with age. In a recent study, [@b66-vhrm-4-1315] showed that administration of the AGE-crosslink breaker, alagebrium, to patients with ISH was associated with improvements in endothelial function, and that this correlated with reductions in vascular fibrosis. The authors hypothesized that by reducing central arterial stiffness and vascular remodeling, these 'destiffening' agents may lower cardiovascular risk in older adults ([@b66-vhrm-4-1315]), however more studies are required to confirm this. Given the relationship between arterial stiffness and cognitive impairment ([@b15-vhrm-4-1315]), such agents may also lead to improvements in cognitive function in elderly patients. Improvements in cognitive function/reduced rate of decline in elderly patients have been suggested for CCBs and ARBs ([@b62-vhrm-4-1315]; [@b16-vhrm-4-1315] [@b50-vhrm-4-1315]).

Conclusions
===========

This review has considered the importance of SBP as a predictor of cardiovascular outcome. It is evident from the data presented that SBP is a better predictor of cardiovascular risk than DBP in most of patients treated with BP lowering agents, and is therefore an appropriate target for antihypertensive therapy. This view is shared by current American and International guidelines on the management of hypertension, both of which place more emphasis on control of SBP than DBP ([@b7-vhrm-4-1315]; [@b64-vhrm-4-1315]). Fixed-dose ARB/CCB combinations offer convenient and potent BP reduction, including powerful reduction of SBP. As a result, these combination treatments are likely to contribute substantially to reducing the risk of cardiovascular events in hypertensive patients.
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**Abbreviations:** AASK, the African American Study of Kidney disease and hypertension; ABCD/NT, Appropriate Blood Pressure Control in Diabetes trial -- tight versus usual blood pressure control in normotensive patients; ALLHAT, Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial; ALLHAT/Aml, Antihypertensive and Lipid- Lowering treatment to prevent Heart Attack Trial -- amlodipine versus chlorthalidone; ALLHAT/Lis, Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial -- lisinopril versus chlorthalidone; ANBP2, Australian comparative outcome trial of angiotensin-converting enzyme inhibitor- and diuretic-based treatment of hypertension in the elderly; ATMH, Australian Trial in Mild Hypertension; CAPPP, CAptopril Prevention Project; CONVINCE, Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints Trial; DIABHYCAR, the non-insulin-dependent DIAbetes, HYpertension, microalbuminuria or proteinuria, Cardiovascular events, and ramipril study; ELSA, European Lacidipine Study on Atherosclerosis; EWPHE, trial conducted by the European Working Party on High blood pressure in the Elderly; HEP, trial of Hypertension in Elderly Patients in primary care; HOPE, Heart Outcomes Prevention Evaluation study; HOT/LH, Hypertension Optimal Treatment trial -- 80 versus 90 mmHg as target diastolic pressure; HOT/MH, Hypertension Optimal Treatment trial -- 85 versus 90 mmHg as target diastolic pressure; IDNT2, Irbesartan Diabetic Nephropathy Trial in patients with type-2 diabetes mellitus; INSIGHT, International Nife-dipine GITS Study -- Intervention as a Goal for Hypertension Treatment; LIFE/All, Losartan Intervention For Endpoint reduction in hypertension study -- all patients; LIFE/DM, Losartan Intervention For Endpoint reduction in hypertension study -- diabetic subgroup; MIDAS/NICS/VHAS, combined results of MIDAS, NICS and VHAS; MRC1, Medical Research Council trial of treatment of mild hypertension; MRC2, Medical Research Council trial of treatment of hypertension in older adults; NICOLE, NIsoldipine in Coronary artery disease in LEuven; NORDIL, NOrdic DILtiazem study; PART2, Prevention of Atherosclerosis with Ramipril Trial; PART2/SCAT, combined results of PART2 and SCAT; PATS, Post-stroke Antihypertensive Treatment Study; PREVENT, Prospective Randomized Evaluation of the Vascular Effects Norvasc Trial; PROGRESS/Com, perindopril PROtection aGainst REcurrent Stroke Study -- group on combined therapy; PROGRESS/Per, perindopril PROtection aGainst REcurrent Stroke Study -- group on single-drug treatment; RENAAL, Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan; RCT70--80, combined results of four smaller trials published from 1970 through 1980, including HSCS, OSLO, USPHS, and VACS; SCOPE, Study on COgnition and Prognosis in the Elderly; SHEP, Systolic Hypertension in the Elderly Program; STONE, Shanghai Trial of Nifedipine in the Elderly; STOP1, Swedish Trial in Old Patients with hypertension; STOP2/ACEIs, angiotensin-converting enzyme inhibitor arm of STOP2; STOP2/CCBs, calcium-channel blocker arm of STOP2; Syst-China, Systolic hypertension in China trial; Syst-Eur, Systolic hypertension in Europe trial; UKPDS, UKPDS hypertension in diabetes study; UKPDS/CA, UKPDS hypertension in Diabetes Study -- captopril versus atenolol; UKPDS/LH, UKPDS hypertension in diabetes study -- low versus high on-treatment blood pressure.](vhrm-4-1315f1){#f1-vhrm-4-1315}
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[@b3-vhrm-4-1315] used data from 8893 treated hypertensive patients and 25,880 untreated age- and gender-matched normotensive and hypertensive control patients to determine the influence of hypertension on cardiovascular mortality. Cardiovascular and coronary mortality were two-fold higher in the treated population. After adjustment for systolic blood pressure (SBP) using Cox regression analysis, the differences between the treated and untreated populations decreased from 96% to 14% (cardiovascular mortality, P = 0.05) and from 99% to 16% (coronary heart disease mortality, p = 0.08). Subsequent adjustment for diastolic blood pressure (DBP) had no further effect on the risk ratios.](vhrm-4-1315f2){#f2-vhrm-4-1315}

![Achievement of blood pressure goals in controlled trials of antihypertensive agents. Reproduced with permission from Mancia G, Grassi G. 2002. Systolic and diastolic blood pressure control in antihypertensive drug trials. *J Hypertens*, 20:1461--4. Copyright © 2002 Lippincott Williams & Wilkins.\
[@b32-vhrm-4-1315] summarized the effects of antihypertensive treatment on systolic and diastolic blood pressure (SBP and DBP, respectively) in clinical trials involving patients with essential hypertension. The data show that higher initial blood pressures (B) are associated with larger reductions during treatment (T). Target blood pressure values (SBP, 140 mmHg; DBP, 85--90 mmHg), shown as dotted lines on the graphs, were achieved more frequently for DBP than for SBP. See [Figure 1](#f1-vhrm-4-1315){ref-type="fig"} legend for key to trial names.](vhrm-4-1315f3){#f3-vhrm-4-1315}

![Percentage of patients who achieved SBP \<140 mmHg and retained DBP ≥ 90 mmHg compared with percentage of patients who achieved DBP \< 90 mmHg and retained SBP ≥ 140 mmHg. Reproduced with permission from Waeber B, Mourad JJ. 2006. Targeting systolic blood pressure: the key to controlling combined systolic/diastolic hypertension. *Am J Hypertens*, 19:985--6. Copyright © 2006 Nature Publishing Group.\
Data from the STRAtegies of Treatment in Hypertension: Evaluation (STRATHE) study show that patients who achieve a target systolic blood pressure (SBP) \< 140 mmHg are also likely to achieve a diastolic blood pressure \< 90 mmHg. In contrast, a substantial proportion of patients who achieve DBP \< 90 mmHg fail to achieve adequate control of SBP. As demonstrated by the figure, this finding is consistent across a range of treatment regimens.](vhrm-4-1315f4){#f4-vhrm-4-1315}

![Systolic blood pressure reductions achieved with a combination of amlodipine and olmesartan ([@b8-vhrm-4-1315]).\
In the COACH study (Combination of Olmesartan medoxomil and Amlodipine besylate in Controlling High blood pressure), patients with a seated diastolic blood pressure of 95--120 mmHg at baseline were randomized to receive daily treatment with placebo, olmesartan/amlodipine 20/5 mg, 40/5 mg, or 40/10 mg. The figure shows the mean reduction from baseline in seated systolic blood pressure (SBP) after 8 weeks of treatment.](vhrm-4-1315f5){#f5-vhrm-4-1315}

###### 

Impact of systolic and diastolic blood pressure on risk of an adverse renal outcome (doubling of serum creatinine or progression to end stage renal disease) (Reproduced with permission from Pohl MA, Blumenthal S, Cordonnier DJ, et al. 2005. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. *J Am Soc Nephrol*, 16:3027--37. Copyright © 2005 American Society of Nephrology).

                           RR     95% CI       P value
  ------------------------ ------ ------------ ----------
  Baseline                                     
    SBP lower by 20 mmHg   0.79   0.71, 0.88   \<0.0001
    DBP lower by 20 mmHg   1.02   0.85, 1.22   0.86
  Achieved                                     
    SBP lower by 20 mmHg   0.52   0.45, 0.60   \<0.0001
    DBP lower by 20 mmHg   1.06   0.84, 1.35   0.61

**Notes:** Relative risks were computed by applying Cox proportional hazards methods to data from 1590 hypertensive patients with type 2 diabetes who were randomized to one of three antihypertensive treatment regimens (irbesartan 300 mg/day, amlodipine 10 mg/day, or placebo). Median patient follow-up was 2.6 years.

**Abbreviations:** CI, confidence interval; DBP, diastolic blood pressure; RR, relative risk; SBP, systolic blood pressure.

###### 

Reductions in systolic and diastolic blood pressure achieved with aliskiren monotherapy and with amlodipine/valsartan, amlodipine/olmesartan, and aliskiren/hydrochlorothiazide combination therapy regimens

  Daily treatment regimen                                             Seated DBP inclusion criteria (mmHg)   n     Mean age (years)   Mean seated BP at baseline (mmHg)   Duration of treatment (weeks)   Mean reduction from baseline in seated BP (mmHg)   Reference                                         
  ------------------------------------------------------------------- -------------------------------------- ----- ------------------ ----------------------------------- ------------------------------- -------------------------------------------------- ------------------------------------------------- ----------------------
  Amlodipine (10 mg)/valsartan (160 mg)                               ≥95 and \<110                          209   56.7               157.4/99.3                          8                               27.8[a](#tfn3-vhrm-4-1315){ref-type="table-fn"}    17.6[a](#tfn3-vhrm-4-1315){ref-type="table-fn"}   [@b43-vhrm-4-1315]
  Amlodipine (5--10 mg)/valsartan (160 mg)                            ≥110 and \<120                         64    56.5               170.8/112.2                         6                               35.8                                               28.6                                              [@b45-vhrm-4-1315]
  Amlodipine (10 mg)/olmesartan (40 mg)                               95*--*120                              162   54.1               165.7/102.4                         8                               30.1                                               19.0                                              [@b8-vhrm-4-1315]
  Aliskiren (150→300 mg)[b](#tfn4-vhrm-4-1315){ref-type="table-fn"}   95*--*109                              560   NR                 NR                                  12                              17.4                                               12.2                                              Schmieder et al 2007
  Aliskiren (300 mg)/HCTZ (25 mg)                                     95*--*109                              173   54.8               154.6/99.3                          8                               21.2[a](#tfn3-vhrm-4-1315){ref-type="table-fn"}    14.3[a](#tfn3-vhrm-4-1315){ref-type="table-fn"}   Villamil et al 2007

least squares mean;

forced titration after 3 weeks.

**Abbreviations:** BP, blood pressure; DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; NR, data not reported; SBP, systolic blood pressure.
